LEXINGTON, Mass., Jan. 7, 2016 /PRNewswire/ -- Pulmatrix, Inc., (NASDAQ: PULM) will present a business update at Biotech Showcase 2016 on Monday, January 11th at 2:30 pm PST (5:30 pm EST). A live webcast of the presentation may be accessed in the investor relations section of the Company's website at www.pulmatrix.com. A replay of the presentation will be available on the Company's website for 90 days following the presentation.
Additionally, the Company will present at the Noble Financial Capital Markets' Twelfth Annual Investor Conference on Tuesday, January 19th at 11:00 am EST. A replay of the video presentation will be available following the conference on January 22, 2016 in the investor relations section of the Company's website (live access will not be available). The webcast and presentation will be archived for 90 days following the event.
About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF), as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD). Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
|
Investor Contact |
Media Contact |
|
Tom Baker |
David Schull, Russo Partners |
|
Direct: 617-532-0624 |
Direct: (858) 717-2310 |
SOURCE Pulmatrix, Inc.